Fabrication nanoparticles carrying the cancer antigen and CpG-rich molecular can cause an immune response in experimental animals

- Theoretical results: The project has developed processes to create chitosan nanoparticles carrying the gene encoding the cancer antigens and CpG-rich molecules capable of enhancing the immune response. Antibodies obtained from rabbits immunized with the recombinant polyepitope EPCA-2 is capable of detecting antigen in serum EPCA-2 is equivalent to commercial ELISA KIT CUSABIO, CSB - EQ 027679HU.
- Applied results: EPCA-2 antibodies obtained after immunization of rabbits with recombinant antigen containing the epitopes (EPCA-2:22 and EPCA-2.19) capable application to determine the amount of EPCA-2 antigen in serum patients for diagnosis and follow-up treatment for prostate cancer.

The project: (1) has fabricated chitosan nanoparticles carrying the gene encoding the cancer antigen and CpG structure capable of enhancing the immune response, (2) has demonstrated the ability obtain antigen-specific antibodies when immunized with the recombinant epitopes of antigen and when immunized with nanostructures carrying gene encoding the antigen and CpG-rich structures, (3) has built the process of creating DNA nanostructures composed both CpG-rich region and the region of genes encoding cancer antigens and this nanostructure can act as a vaccine for the prevention and  treatment of cancer.

- Scientific papers in referred journals (list):
1) Duong L.T.T, Phuc P.V., Lua D.T.M, Huyen La Thi, Anh T.T., and Huan Le Quang, (2014). Using the DNA-Chitosan complex as vaccine nanoparticle in cancer. Global Science Research Journal, Vol. 2 (5).pp. 92-97. ISSN: 2408-5502.
2) Anh Dam Thi Tu, Phuc Le Thi, Hien Ngo Thu Thi, Huan Le Quang, (2014). Researching in Immune Response of PolEPCA-2 Recombinant Antigen Specific for Prostate Cancer. Inter. J. Science and Research. (accept. Pub)
3) Hien Ngo Thi Thu, Anh Dam Thi Tu, Phuc Le Thi, Huan Le Quang, Ngoc Thien Pham, ((2014). Expression of gene encoding for polyepitope of early prostate cancer antigene (EPCA-2) in Escherichia coli. Clinical medicine, 80: 74-81.

- Patents (list): Huan Le Quang, Huyen La Thi, Huyen Nguyen Thi Minh, Thuy Nguyen Thi Thu, (2013). The nanostructure having capable of targeted drug delivery and enhance the immune response in cancer treatment. Date of filing: 3/5/2013, Date of acceptance of valid application: 16/8/2013.

- Technological products (describe in details: technical characteristics, place):
(1) The gene encoding the epitope-EPCA- 2:22 and EPCA-2:19 of EPCA-2 antigen; (2) The recombinant gene encoding the epitope of HER2 antigen and CpG-rich molecular capable of enhancing the immune response; (3) The nanostructure containing gene encoding cancer antigens and CpG-rich molecular. These products have been stored in Lab. Animal Cell Technology, Institute of Biotechnology, VAST (address: Room 407, B4, 18 Hoang Quoc, Hanoi, Vietnam).

- Other products (if applicable):
1) MSc Nga Hoang Thi, Hanoi University of Sciences, VNU. Thesis title: "Research manufacturing nano-chitosan complex carries Telomerase Reverse Transcriptase genes (hTERT). Dated: 04.26.2014 has been issued “The Degree of Master” with No: DM 017386.
2) MSc. Doctor. Boarding, Hien Ngo Thi Thu, Hanoi Medical University. Thesis title: "The study of gene expression encoded polyepitope for early prostate cancer antigen (EPCA-2) in the E. coli. Protected and has been granted by the number: 001 485, date 03.06.2014
3) PhD. Student Anh Dam Thi Tu, Hanoi Medical University. Thesis title: Study obtaining antigen-specific antibodies for prostate cancer in diagnostic applications. "Base Defended, date 01/07/2015.